Get the Stockscreener App
0.8128
0.66%
-0.0052
Cardiff Oncology Inc stock is traded at $0.8128, with a volume of 989.68K.
It is down -0.66% in the last 24 hours and down -36.02% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$0.818
Open:
$0.8
24h Volume:
989.68K
Relative Volume:
0.69
Market Cap:
$62.69M
Revenue:
$525.00K
Net Income/Loss:
$-44.76M
P/E Ratio:
-1.2219
EPS:
-0.6652
Net Cash Flow:
$-37.46M
1W Performance:
-5.51%
1M Performance:
-36.02%
6M Performance:
-49.68%
1Y Performance:
-75.45%
1-Day Range:
$0.7566
$0.8199
1-Week Range:
$0.7566
$0.859
52-Week Range:
$0.7566
$3.31
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
0.8058 | 65.03M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
488.19 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.92 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
883.32 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
285.55 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Cardiff Oncology completes $10 million financing transaction - TipRanks
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock - Investing.com UK
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock By Investing.com - Investing.com Nigeria
Form 4 Cardiff Oncology Inc For: 16 July By Investing.com - Investing.com Nigeria
Cardiff Oncology Director Purchased Shares Worth Over $999K - TradingView
Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing - marketscreener.com
Cardiff Oncology (CRDF) director buys 687,285 shares and warrants - Stock Titan
Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake - Stock Titan
Cardiff Oncology Raises $10M for Onvansertib Regulatory Push - AllSci
Cardiff Oncology Announces $10 Million Registered Direct Offering to Advance Cancer Therapy Pipeline - Minichart
Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright - TradingView
Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing - Stock Titan
Cardiff Oncology announces $10M direct offering - MSN
Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June - Sahm
Cardiff Oncology to Raise $10 Million in Share, Warrant Sale - Moomoo
Cardiff Oncology prices $10M registered direct offering - Investing.com UK
Cardiff Oncology prices $10M registered direct offering By Investing.com - Investing.com South Africa
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital - Yahoo Finance
Cardiff Oncology Announces $10 Million Registered Direct Offering - The Manila Times
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – FWB:XE7C - TradingView
CRDF Q1 2026 Earnings: EPS Miss Sends Mixed Signals Despite Modest Stock GainPerformance Review - dars.gov.et
Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary - Quartr
Price to earnings forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
Price to earnings forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Cardiff Oncology (CRDF) Rises 3.85% as Biotech Stock Tests Key Resistance ZoneDark Pool Sentiment - po-news-eg.net
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Price to book forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
Cardiff Oncology (CRDF) Falls as Stock Nears Critical Support ZoneCup and Handle - dars.gov.et
CRDFCardiff Oncology Inc Dividends - Finviz
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer |
Jul 14 '26 |
Buy |
1.46 |
34,364 |
50,000 |
59,067 |
| Mohindru Mani | Chief Executive Officer |
Jun 18 '26 |
Buy |
1.21 |
24,703 |
29,891 |
24,703 |
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
275,000 |
673,750 |
1,330,676 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
0.24%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):